Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

AUD/USD Forex Technical Analysis – Strengthens Over .6893, Weakens Under .6876

Based on the early price action and the current price at .6884, the direction of the AUD/USD the rest of the session on Thursday is likely to be determined by trader reaction to the 50% level at .6876 and the downtrending Gann angle at .6893. James Hyerczyk ...
FX Empire | December 12, 2019 |

Massive Reversal in Precious Metals but Fundamentals Improving

To underscore the volatility of this past week, consider the price action in Silver. Silver, days ago, had a chance to make its highest monthly close since October 2016. That is well over three years ago. Silver closed the week and the month at its lowest levels in six mon...
Jordan Roy-Byrne, CMT | March 2, 2020 |

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. ...
Mario Hose | September 29, 2020 |

Turning Over a New Leaf. Environmentally and Profitably

(Click image to play video) They’re the company that’s delivering “better everyday products from plants, not petroleum.” And they’re good natured ® Products Inc. ( TSX-V: G...
Dave Jackson | June 7, 2021 |

Is Widening Yield Curve Inversion Lifting Gold Prices Up?

The yield curve inversion just got more pronounced. Not only the spread between 10-year and 3-month Treasuries, now also the spread between 10-year and 2-year turned negative. That sends a warning signal about the state of the real economy. About a recession on the horizon. So...
Arkadiusz Sieron | August 15, 2019 |

Gold in the Negative Real Interest Rates Environment

Many believe that negative interest rates will never arrive to the United States. This can’t possibly happen here. The discussions of their theoretical benefits almost remind you of the not-in-my-backyard mentality. But this is not true – they are already prese...
Arkadiusz Sieron | October 8, 2019 |

The Narrative About Gold is Changing Again

Teaser: Let’s face it, we live in a world of radical uncertainty. Yet we’re supposed to make perfectly rational decisions – so, how do we cope with the unknown? We tell narratives, and form our decisions around them! Let’s...
Arkadiusz Sieron | December 2, 2019 |

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen

Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. Shares of ph...
Streetwise Reports | December 13, 2019 |

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data

Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. ...
Streetwise Reports | April 7, 2020 |

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. ...
Streetwise Reports | April 28, 2020 |
1 2 3